Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.

@article{Kudoh1998PhaseIS,
  title={Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.},
  author={Shinzoh Kudoh and Yoshinori Fujiwara and Yoshiki Takada and Hidehiko Yamamoto and Akitoshi Kinoshita and Yutaka Ariyoshi and Kiyoyuki Furuse and Masahiro Fukuoka},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 3},
  pages={1068-74}
}
PURPOSE Irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC) as monotherapy. Cisplatin is also a key drug against SCLC. We conducted a phase II study of CPT-11 combined with cisplatin to evaluate the efficacy and toxicity of this regimen in patients with previously untreated SCLC. PATIENTS AND METHODS Seventy-five patients with previously untreated SCLC were enrolled onto the study. CPT-11 60 mg/m2 was administered intravenously on days 1, 8, and 15 in combination with… CONTINUE READING
47 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…